NUCLEAR MEDICINE
Nuclear medicine in Turkey: imaging and radioligand therapy
Nuclear medicine can be used for imaging and, in selected cancers, for treatment with radiopharmaceuticals. Eligibility depends on the exact diagnosis, disease distribution, prior therapy, imaging and organ function.
Medical decisions are made by the evaluating physicians and hospitals. MEDITRAVEL coordinates access and communication.
PATIENT DECISION PATHWAY
01
Diagnosis
Pathology · stage · imaging
02
Right team
Hospital · physician · tumour board
03
Decision
Plan · timeline · estimated cost
Common questions
PSMA PET/CT
An imaging test used in selected prostate-cancer settings; it is not itself a treatment.
Lutetium-177 PSMA
A radioligand therapy used for selected patients with advanced prostate cancer when specific criteria are met.
Neuroendocrine tumours
Peptide receptor radionuclide therapy may be considered in selected receptor-positive neuroendocrine tumours.
Safety review
Blood counts, kidney function and previous treatments may be part of eligibility assessment.
A positive scan does not automatically mean treatment is indicated
Imaging, clinical status and prior treatment history must be interpreted together by the nuclear medicine and oncology team.
Related MEDITRAVEL information
Last editorial update: 2026-10-10. Medical background: NCI/ESMO. Hospital facts: public institutional sources and MEDITRAVEL partner pages. Sources & methodology.